Mentype® AMLplexQS allows the identification of 11 gene fusions and 34 transcript variants associated with acute myeloid leukaemia (AML).

The assay is based on a multiplex PCR reaction with subsequent fragment analysis by capillary electrophoresis. RNA isolated from blood or bone marrow must first be transcribed into cDNA. Primers are fluorescence-labeled with 6-FAM™, BTG or BTY, allowing rapid and sensitive analysis by the aforementioned capillary electrophoresis.

The amount of isolated RNA and the quality of the reverse transcription reaction will be shown by the included ABL control. Successful multiplex amplification is monitored by a control-amplification of the internal quality sensor “QS”. Furthermore, a cDNA carrying the AML1-ETO translocation is enclosed as a positive control.
Mentype® AMLplexQS represents your reliable diagnostics for precise, highly sensitive and routine-fit analysis of fusion gene transcripts in acute myeloid leukaemia.